On Monday, AstraZeneca Plc AZN shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for ...
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...
Clinical Trials Arena on MSN
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response
Despite the primary endpoint miss, AstraZeneca hopes to bring efzimfotase alfa to patients with hypophosphatasia.
Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...
Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing ...
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...
Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca is investing $2 billion in Miami-based Summit Therapeutics as the pharmaceutical giant deepens its relationship ...
AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with antibody-drug conjugates (ADCs). The newly minted ...
Marc Zerbola Challande is a news reporter at Investopedia. Marc also co-founded Guerilla Capital, which provided marketing services for Canadian-listed firms. David Kindness is a Certified Public ...
Myriad Genetics, SOPHiA GENETICS and AstraZeneca are collaborating to advance Myriad’s prostate cancer genomic instability ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results